Translin-Trax: Considerations for Oncological Therapeutic Targeting

Ramsay J McFarlane; Jane A Wakeman

doi:10.1016/j.trecan.2020.02.014

Translin-Trax: Considerations for Oncological Therapeutic Targeting

Trends Cancer. 2020 Jun;6(6):450-453. doi: 10.1016/j.trecan.2020.02.014. Epub 2020 Mar 16.

Authors

Ramsay J McFarlane¹, Jane A Wakeman²

Affiliations

¹ North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK. Electronic address: r.macfarlane@bangor.ac.uk.
² North West Cancer Research Institute, School of Medical Sciences, Bangor University, Deiniol Road, Bangor, Gwynedd LL57 2UW, UK.

PMID: 32460000
DOI: 10.1016/j.trecan.2020.02.014

Abstract

Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consider how this complexity could influence therapeutic design strategies.

Keywords: DNA repair; Dicer; Translin-Trax; drug development; miRNA.

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Carcinogenesis / drug effects
Carcinogenesis / genetics
DEAD-box RNA Helicases / metabolism
DNA Breaks, Double-Stranded
DNA End-Joining Repair / drug effects
DNA-Binding Proteins / antagonists & inhibitors*
DNA-Binding Proteins / metabolism
Drug Design
Gene Expression Regulation, Neoplastic / drug effects
Genes, Tumor Suppressor
Humans
MicroRNAs / metabolism
Molecular Targeted Therapy / methods
Neoplasms / drug therapy*
Neoplasms / genetics
RNA Precursors / metabolism*
RNA Stability / drug effects
Ribonuclease III / metabolism

Substances

Antineoplastic Agents
DNA-Binding Proteins
MicroRNAs
RNA Precursors
TSN protein, human
TSNAX protein, human
DICER1 protein, human
Ribonuclease III
DEAD-box RNA Helicases